GlassScriptPhysician profile
Mohammed Abo Khamis
NPI 1508098419
$1,243.66
in general payments reported to CMS, 2019-2025
15 companies · $81.32 in 2025
The $81.32 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $147 · 2021: $47.02 · 2022: $468 · 2023: $108 · 2024: $260 · 2025: $81.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $241 · Food and Beverage: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $240.99 |
| Food and Beverage | $208.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $366.91 | 2022-2024 | |
| Astellas Pharma US INC | $291.71 | 2023-2025 | Cresemba |
| Astrazeneca Pharmaceuticals LP | $173.35 | 2019-2024 | Andexxa |
| Merck Sharp & Dohme LLC | $104.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $49.83 | 2022-2024 | |
| Pfizer INC. | $47.53 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $38.17 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $36.52 | 2020 | |
| Abbott Laboratories | $33.65 | 2025 | Amplatzer Amulet |
| Penumbra, INC. | $25.63 | 2025 | Indigo System |
| Ucb, INC. | $19.01 | 2021 | |
| Philips North America LLC | $17.60 | 2020 | |
| Gilead Sciences, INC. | $13.81 | 2021 | |
| Scpharmaceuticals INC. | $13.17 | 2023 | |
| Xeris Pharmaceuticals, INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Abo Khamis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.